Summary: Integrated Model of Immune Dysfunction
The immune abnormalities in ME/CFS form a coherent, if complex, picture (Walitt et al. 2024):
Triggering event: Infection or other immune challenge initiates the process
Innate immune dysfunction: NK cells and other innate effectors fail to clear the pathogen or control reactivation
Chronic antigenic stimulation: Persistent infection or autoimmunity drives ongoing B cell activation, producing the characteristic naïve B cell expansion and switched memory B cell depletion documented by the NIH study
Autoantibody development: Aberrant B cell responses generate autoantibodies targeting receptors and other self-antigens
T cell exhaustion: Chronic stimulation exhausts T cell responses
Cytokine dysregulation: Ongoing inflammation produces symptom-causing cytokines
Sex-specific patterns: Men and women show different immune abnormalities, suggesting distinct pathophysiological pathways
Neuroinflammation: Peripheral immune signals affect brain function, contributing to fatigue and cognitive symptoms
Mast cell involvement: Mast cell activation may amplify symptoms in susceptible individuals
This sequence represents one plausible ordering of events; many steps may occur in parallel, and the sequence may vary between patients or subgroups. For example, autoantibody development (step 4) could precede, follow, or coincide with T cell exhaustion (step 5), and sex-specific immune patterns (step 7) likely influence all stages rather than emerging at a discrete point.
This model provides multiple potential therapeutic targets: antiviral agents for persistent infection, immunomodulators for autoimmunity, mast cell stabilizers for those with MCAS, and anti-inflammatory approaches for cytokine-mediated symptoms. The recognition of sex-specific immune patterns may eventually enable personalized treatment selection.
The integrated model above presents a coherent narrative, but it must be reconciled with a striking pattern of null results from well-powered studies. Comprehensive viral screening (Lipkin: 391 patients, no pathogen differences; Davis/Stanford: 185 viruses in severe patients, more viruses in controls), broad autoantibody profiling (Germain 2025: 7,542 interactions, complete null ), cytokine meta-analysis (Corbitt 2019: “of 64 cytokines, none differ consistently” (Corbitt et al. 2019)), and multi-site NK assessment (MCAM: \(p = 0.79\) (Querec et al. 2023)) have all failed to find systemic immune signatures proportionate to the severity of disability.
This generates a fundamental puzzle: what immune mechanism is potent enough to cause extreme disability yet leaves no measurable trace in blood, saliva, or stool?
Three frameworks can account for this paradox:
Compartmentalised immunity: The pathology resides in tissues that blood sampling cannot access—gut mucosa, dorsal root ganglia, brain parenchyma, lymph node microenvironments. Peluso et al. (2024) demonstrated SARS-CoV-2 viral persistence in gut tissue biopsies of Long COVID patients with no detectable virus in blood, proving this is biologically possible (Peluso et al. 2024). Further supporting this compartmentalised pathology model, Eberhardt et al. (2023) found SARS-CoV-2 spike protein persisting in coronary plaque macrophages with pro-atherogenic gene activation, and viral RNA was detected in plaques two years post-infection (Eberhardt et al. 2023). Blood-based studies may be systematically missing the relevant compartment.
The exhaustion interpretation: Hornig et al. documented that cytokine elevations occur in early ME/CFS (\(<\) 3 years) but normalize in chronic disease . By the time patients enter research studies (often after years of illness), the inflammatory fire has burned out. The null results in chronic cohorts may accurately reflect late-stage immunology while missing the critical early window.
Post-immune damage: The immune trigger was transient but caused permanent downstream damage—metabolic reprogramming, epigenetic changes, structural neurological alterations—that persists independently of ongoing immune activity. In this framework, the immune system is now genuinely normal, and the null results are correct; the damage is done and self-sustaining through non-immune mechanisms.
These frameworks make different predictions. Compartmentalised immunity predicts tissue biopsy abnormalities with normal blood values. Exhaustion predicts that early-onset patients (\(<\) 3 years) will show blood abnormalities that chronic patients lack. Post-immune damage predicts that even early-onset patients will show normal blood immunity if studied after the acute trigger resolves, but will show metabolic or structural changes detectable by non-immune assays. Distinguishing among these is among the highest priorities in ME/CFS research.
Certainty: 0.35. Integrative framework consistent with the overall pattern of null blood-level results alongside positive functional results. Not directly tested as a unified hypothesis.
The pattern of immune findings in ME/CFS is not one of immune activation or immune suppression—it is one of immune cell incompetence. Individual immune cells are structurally present in normal numbers and proportions but functionally impaired at the level of intracellular machinery:
- NK cells: Normal counts, impaired cytotoxicity (Hedges’ g = 0.96 )
- T cells: Normal proportions, reduced glycolysis and metabolic dysfunction
- B cells: Normal counts, skewed repertoire without adaptive signatures (Ryback and Cowan 2025)
- Cytokines: Normal circulating levels, but individual cells may fail to produce appropriate bursts upon stimulation
- Autoantibodies: Not detectable by broad screening , yet functional assays and treatment responses suggest pathology
This framework—“normal army, broken soldiers”—predicts that functional assays (cytotoxicity, proliferation upon stimulation, class switching capacity, metabolic flux) will consistently show abnormalities even when phenotypic assays (cell counts, surface markers, resting cytokine levels) are normal. The TRPM3 calcium channel dysfunction (Section Arginine Depletion as the Nutritional Choke-Point Linking MDSC Expansion to NK Metabolic Failure) provides a concrete molecular mechanism: if calcium signaling is globally impaired in immune cells, every downstream function—degranulation, proliferation, cytokine burst, metabolic activation—is compromised. The cell is present but cannot execute its programs.
Therapeutic implication: If verified, this framework redirects therapeutic strategy from immunosuppression (which has consistently failed: anakinra, rituximab in the RCT) toward immune cell repair—restoring intracellular signaling capacity (TRPM3 modulators), metabolic rescue (CoQ10, NAD+ precursors), and mitochondrial support rather than dampening immune output that is already inadequate.
Falsification: The framework would be falsified if large studies using standardized functional assays (not just phenotypic counts) consistently find normal immune cell function in ME/CFS, or if a systemic circulating signal (cytokine, autoantibody, pathogen) is identified that fully explains the disability.